NCIt definition : An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic
activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents
the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents
both B-cell activation and BTK-mediated activation of downstream survival pathways.
This leads to an inhibition of the growth of malignant B cells that overexpress BTK.
BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is
overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development,
activation, signaling, proliferation and survival.;
UNII : I42748ELQW;
InChIKey : WDENQIQQYWYTPO-IBGZPJMESA-N;
CAS number : 1420477-60-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1420477-60-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;